Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NovaBay Pharmaceuticals (NBY) Net Margin (2016 - 2025)

Historic Net Margin for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to 248.18%.

  • NovaBay Pharmaceuticals' Net Margin changed N/A to 248.18% in Q3 2025 from the same period last year, while for Sep 2025 it was 24.32%, marking a year-over-year increase of 2428600.0%. This contributed to the annual value of 88.01% for FY2024, which is 742800.0% up from last year.
  • NovaBay Pharmaceuticals' Net Margin amounted to 248.18% in Q3 2025.
  • In the past 5 years, NovaBay Pharmaceuticals' Net Margin ranged from a high of 3.39% in Q1 2022 and a low of 449.26% during Q4 2023
  • Over the past 5 years, NovaBay Pharmaceuticals' median Net Margin value was 94.11% (recorded in 2021), while the average stood at 125.53%.
  • Per our database at Business Quant, NovaBay Pharmaceuticals' Net Margin crashed by -2240100bps in 2023 and then surged by 4368700bps in 2024.
  • Over the past 5 years, NovaBay Pharmaceuticals' Net Margin (Quarter) stood at 28.14% in 2021, then tumbled by -700bps to 225.25% in 2022, then tumbled by -99bps to 449.26% in 2023, then soared by 97bps to 12.39% in 2024, then plummeted by -1903bps to 248.18% in 2025.
  • Its last three reported values are 248.18% in Q3 2025, 12.39% for Q4 2024, and 66.04% during Q2 2024.